01 Development of Miniaturized Ventricular Assist Devices Ventricular assist devices are becoming smaller through improvements in pump design and device components. Compact systems can simplify implantation and improve patient mobility during long-term circulatory support. This development makes ventricular assist therapy more compact and patient-friendly.
02 Expansion of Percutaneous Temporary Cardiac Support Devices The cardiac assist devices market analysis shows that percutaneous cardiac support devices are being used more widely to provide short-term circulatory support through catheter-based procedures. These devices can assist the heart during conditions such as cardiogenic shock and high-risk cardiac procedures. This trend expands the use of temporary mechanical support in acute cardiac care.
01 Supply chain disruptions are expected to have a substantial impact on the cardiac assist devices market share, as production depends on specialized electronics, pumps, precision components, and sterile medical-grade materials. The market is likely to follow a U-shaped recovery pattern, as shortages can persist while alternative components and suppliers undergo quality and regulatory qualification before production can fully recover. The market is expected to grow at a CAGR of 9.10%, but supply chain constraints could approximately lower this by 0.5 percentage points, resulting in short-term growth of around 8.6%. As specialized component availability, supplier qualification, sterile manufacturing capacity, and medical device logistics stabilize, cardiac assist device market growth is expected to gradually return to 9.10%.
01 The cardiac assist devices market forecasts strategic investment activity driven by next-generation ventricular assist devices, minimally invasive percutaneous pumps, and technologies aimed at improving treatment for cardiogenic shock and heart failure.
02 Key Investment and Funding Activities in the Cardiac Assist Devices Market, 2025–2026 Company Value (USD) Details VenstraMedical ~USD 1 Million In 2025, VenstraMedical received a US$1 million grant through MTPConnect's Targeted Translation Research Accelerator under Australia's Medical Research Future Fund. The funding supports development of its next-generation percutaneous ventricular assist device. Enginprime Medical ~USD 12 Million In August 2026, Enginprime Medical raised USD 12 million in Series A funding, led by Qiming Venture Partners. The proceeds will fund the China registration clinical trial of its OpusOne percutaneous ventricular assist device, as well as regulatory submissions and early-stage clinical development in global markets.
01 Need to Curb Advanced Refractory Heart Failure Rate and Focus on Destination Therapy Drive Market The growing clinical need for long-term circulatory support among patients with advanced refractory heart failure supports the demand for ventricular assist devices (VADs). The FDA maintains indications for left ventricular assist device (LVAD) systems for patients with advanced heart failure requiring short or long-term mechanical circulatory support (MCS), including destination therapy.The use of destination therapy also expands the addressable patient pool beyond those awaiting heart transplantation. Patients who are not transplant candidates or are unlikely to receive a donor heart use durable cardiac pumps for long-term circulatory support, supporting continued LVAD utilization.
01 Anticoagulation Requirements and Device-Related Infection Risks Restrict Market Expansion Patients supported by durable VAD systems often require ongoing anticoagulation and close monitoring to manage thrombotic complications. This increases treatment complexity and limits use among patients with high bleeding risk.Implanted pumps also involve driveline and surgical site management throughout treatment. Infection prevention and repeated clinical monitoring add to the care burden associated with durable cardiac assist devices.
01 Pediatric Circulatory Support Systems and Remote Device Monitoring Offer Growth Opportunities to Market Players Manufacturers can develop smaller VADs and specialized systems for pediatric patients with severe cardiac conditions. Dedicated pediatric platforms address anatomical and flow requirements that differ from adult circulatory support applications.Remote monitoring platforms also create opportunities to track pump parameters, battery status, alarms, and patient condition outside the hospital. Integration with critical care and home follow-up services can support long-term management of patients receiving circulatory support.